Iridex EV/EBIT IRIX

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2013.

Today, Oct 23, 2026: n/m; an operating loss
Last meaningful: 313×; Nov 2016
Peer median: 8.2×

Iridex has no meaningful EV/EBIT today: it made an operating loss of $2.8M over the last twelve months.

It was last meaningful in Nov 2016, at 313×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2016	313×	100×	376×
2015	105×	23.8×	112×
2014	33.4×	24.6×	38.2×
2013	33.9×	28.1×	52.0×

Against its peers

Companies in Healthcare nearest Iridex's size, closest first, today.

Company	EV/EBIT
IRIXIridex	n/m
NEPHNephros	20.5×
ATNMActinium Pharmaceuticals	1.2×
APTAlpha Pro Tech	8.2×
SPROSpero Therapeutics	2.1×
LFVNLifevantage	9.6×
ICCCImmucell	14.2×
KEQUKewaunee Scientific	7.2×
Peer median	8.2×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Iridex

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.